WHO: Small cancer risk after Fukushima accident


LONDON (AP) — People exposed to the highest doses of radiation during Japan's Fukushima nuclear plant disaster in 2011 may have a slightly higher risk of cancer but one so small it probably won't be detectable, the World Health Organization said in a report released Thursday.


A group of experts convened by the agency assessed the risk of various cancers based on estimates of how much radiation people at the epicenter of the nuclear disaster received, namely those directly under the plumes of radiation in the most affected communities in Fukushima, a rural agricultural area about 150 miles (240 kilometers) north of Tokyo.


Some 110,000 people living around the Fukushima Dai-ichi nuclear plant were evacuated after the massive March 11, 2011, earthquake and tsunami knocked out the plant's power and cooling systems, causing meltdowns in three reactors and spewing radiation into the surrounding air, soil and water.


Experts calculated that people in the most affected regions had an additional 4 to 7 percent overall risk of developing cancers, including leukemia and breast cancer. In Japan, men have about a 41 percent lifetime risk of developing cancer of an organ, while a woman's lifetime risk is about 29 percent. For those most hit by the radiation after Fukushima, their chances of cancer would rise by about 1 percent.


"These are pretty small proportional increases," said Richard Wakeford of the University of Manchester, one of the authors of the report.


"The additional risk is quite small and will probably be hidden by the noise of other (cancer) risks like people's lifestyle choices and statistical fluctuations," he said. "It's more important not to start smoking than having been in Fukushima."


Experts had been particularly worried about a spike in thyroid cancer, since iodine released in nuclear accidents is absorbed by the thyroid, especially in children. After the Chernobyl disaster, about 6,000 children exposed to radiation later developed thyroid cancer because many drank contaminated milk after the accident.


In Japan, dairy radiation levels were closely monitored, but children are not big milk drinkers there.


WHO estimated that women exposed as infants to the most radiation after the Fukushima accident would have a 70 percent higher chance of getting thyroid cancer in their lifetimes. But thyroid cancer is extremely rare and the normal lifetime risk of developing it is about 0.75 percent. That lifetime risk would be 0.5 percent higher for those women who got the highest radiation doses as babies.


Wakeford said the increase in such cancers may be so small it will probably not be observable.


For people beyond the most directly affected areas of Fukushima, Wakeford said the projected risk from the radiation dropped dramatically. "The risks to everyone else were just infinitesimal."


Some experts said it was surprising that any increase in cancer was even predicted and believe that the low-dose radiation people in Fukushima received hasn't been proven to raise the chances of cancer.


"On the basis of the radiation doses people have received, there is no reason to think there would be an increase in cancer in the next 50 years," said Wade Allison, an emeritus professor of physics at Oxford University, who was not connected to the WHO report. "The very small increase in cancers means that it's even less than the risk of crossing the road," he said.


Gerry Thomas, a professor of molecular pathology at Imperial College London, accused the WHO of hyping the cancer risk.


"It's understandable that WHO wants to err on the side of caution, but telling the Japanese about a barely significant personal risk may not be helpful," she said.


Thomas said the WHO report used inflated estimates of radiation doses and didn't properly take into account Japan's quick evacuation of people from Fukushima.


"This will fuel fears in Japan that could be more dangerous than the physical effects of radiation," she said, noting that people living under stress have higher rates of heart problems, suicide and mental illness.


___


Mari Yamaguchi in Tokyo contributed to this report.


Read More..

Wall Street advances, on track for third day of gains

NEW YORK (Reuters) - U.S. stocks edged higher on Thursday, pointing to a third straight day of gains in the wake of some strong economic data, though a further advance may be limited with major averages near multi-year highs.


While some data released Thursday were rosy, a read on economic growth was weaker than expected, and analysts said a pullback may be in store a day after major equity indexes posted their biggest daily advance since early January.


Over the past two sessions, the S&P 500 has gained 1.9 percent, rising back above the closely watched level of 1,500. The Dow Jones industrial average moved within striking distance of an all-time high.


"The market is looking choppy, and I think investors should use this as an opportunity to sell into strength," said Matt McCormick, a money manager at Cincinnati-based Bahl & Gaynor. "This seems like an environment where someone should be conservative instead of aggressive."


The U.S. economy grew 0.1 percent in the fourth quarter, a weaker pace than expected, although a slightly better performance in exports and fewer imports led the government to scratch an earlier estimate of an economic contraction.


Separately, the number of Americans filing new claims for unemployment benefits fell more than expected last week, while the February Chicago Purchasing Managers Index unexpectedly rose to an 11-month high.


While equity markets suffered steep losses earlier in the week on concerns over European debt, they have since recovered, with the gains fueled by strong data and recent comments by Federal Reserve Chairman Ben Bernanke that showed continued support for the Fed's economic stimulus policy.


"Growth is still anemic and there are still issues with Europe. People seem to be ignoring the signs that would otherwise give them cause for concern," said McCormick, who helps oversee $8.2 billion in assets.


The Dow Jones industrial average <.dji> was up 27.27 points, or 0.19 percent, at 14,102.64. The Standard & Poor's 500 Index <.spx> was up 5.13 points, or 0.34 percent, at 1,521.12. The Nasdaq Composite Index <.ixic> was up 13.75 points, or 0.43 percent, at 3,176.01.


The benchmark S&P 500 has gained 1.4 percent in February, the Dow is up 1.7 percent and the Nasdaq has added 1 percent.


J.C. Penney Co Inc slumped 18 percent to $17.32 as the S&P's biggest decliner after the department store reported a steep drop in sales on Wednesday. Groupon Inc also slumped on weak revenue, with the stock off 25 percent at $4.50.


Mylan Inc jumped 6.5 percent to $30.45 on the Nasdaq after the generic drugmaker posted a 25 percent rise in fourth-quarter profit.


Investors were keeping an eye on the debate in Washington over sequestration - U.S. government budget cuts that will take effect starting on Friday if lawmakers fail to reach an agreement on spending and taxes. President Barack Obama and Republican congressional leaders arranged to hold last-ditch talks to prevent the cuts, but expectations were low that any deal would be produced.


With 93 percent of the S&P 500 companies having reported results so far, 69.5 percent have beaten profit expectations, compared with a 62 percent average since 1994 and 65 percent over the past four quarters, according to Thomson Reuters data.


Fourth-quarter earnings for S&P 500 companies are estimated to have risen 6.2 percent, according to the data, above a 1.9 percent forecast at the start of the earnings season.


(Editing by Bernadette Baum)



Read More..

Dancing with the Stars: Kellie Pickler Calls Partner Derek Hough an 'Answered Prayer'















02/27/2013 at 10:35 AM EST







Kellie Pickler and Derek Hough


Getty(2)


When country singer Kellie Pickler found out Derek Hough would be her Dancing with the Stars pro partner, the first person she wanted to thank was her grandfather, Ken Morton.

"Having Derek as my partner is an answered prayer," Pickler tells PEOPLE. "Right before I left Nashville for L.A., my Grandpa Ken, who is a huge fan of the show, told me he was praying that Derek would be my partner, because that's his favorite male dancer on the show."

Picker, 26, made a splash on season 5 of American Idol, which films at a soundstage next door to Dancing with the Stars. Now she hopes that returning to the building where her career got its start and teaming with three-time DWTS champ Hough, whom she calls "a phenomenal dancer," will bring her luck in the pursuit of the coveted mirror-ball trophy.

And for good measure, she's counting on her Grandpa Ken.

"Now I think I will tell him to pray that we win!" Pickler says.

Dancing's new season kicks off March 18 on ABC.

Read More..

Vt. lye victim gets new face at Boston hospital


BOSTON (AP) — A Vermont woman whose face was disfigured in a lye attack has received a face transplant.


Doctors at Boston's Brigham and Women's Hospital say 44-year-old Carmen Blandin Tarleton underwent the surgery earlier this month.


A team worked 15 hours to transplant the facial skin, including the neck, nose, lips, facial muscles, arteries and nerves.


The 44-year-old Tarleton, of Thetford, Vt., was attacked by her former husband in 2007. He doused her with industrial strength lye. She suffered chemical burns over 80 percent of her body. The mother of two wrote a book about her experience that describes her recovery.


It was the fifth face transplant at the Boston hospital.


Physicians are planning to discuss the case Wednesday at the hospital.


Read More..

Wall Street inches up after data

MADRID, Feb 27 (Reuters) - Lionel Messi has rarely been accused of failing to deliver in big games, having scored in two European Cup finals, but after subdued performances against AC Milan and Real Madrid, questions are being asked. The four-times World Player of the Year and leading scorer in one of the greatest club teams of all time, was a shadow of his usual self at the San Siro in a Champions League last-16 first leg last week, when Barcelona slumped to a 2-0 defeat. ...
Read More..

Rick Springfield Returns to General Hospital with Real-Life Son!















02/26/2013 at 10:40 AM EST



The doctor is in. Again.

Rick Springfield, 63, will reprise his role as Dr. Noah Drake on General Hospital for several episodes in April, he tells PEOPLE exclusively.

As the ABC soap opera marks its 50th anniversary, the "Jessie's Girl" singer will also be joined by his son, Liam Springthorpe, who will make his debut appearance on the show as an undercover cop.

Springfield, who last appeared on the show in March 2012, says the good doctor has a lot of personal baggage to deal with.

"He lost his wife and became a drunk and regretted all these terrible, sinful ways and then cleaned his act up when he almost died from the alcohol," says Springfield. "Now he disappears all the time, going to Doctors Without Borders and going around the world helping people. I guess he's gone from a drunk to being incredibly altruistic. I'm not nearly as altruistic as Noah Drake is."

Rick Springfield Returns to General Hospital with Real-Life Son!| General Hospital, TV News, Rick Springfield

Liam Springthorpe

Bjorn Photography

Springfield, who hasn't begun filming yet, looks forward to seeing his former costars again.

"I don't think any of us are good at keeping in touch," he says. "It's like workmates that you like, or you get together with an old band and you are instantly back to where you were. There's nothing that needs to be maintained. It wasn't that kind of friendship. It was a work thing."

Springthorpe says he "feels a bit weird" being on the same show as his father, but he's "putting aside the fact that this show sort of launched my dad and just kind of taking it for what it is."

As far as they know, they do not have any scenes together, but Springthorpe actually finds that a relief.

"I think it makes it much more pleasing and applicable for me because I think at least for me personally, I have always tried to keep a bit of distance from … my father's path, and respectfully so," Springthorpe, who has own band called History Lessons, says. "I think this is a really good way to kind of go about getting my foot in the door, meanwhile being comfortable in the process."

PEOPLE Celebrates General Hospital hits newsstands nationwide on March 1, and is also available in hardcover wherever books are sold on March 12. Buy yours on Amazon today!

Read More..

Consumer confidence rebounds in February


NEW YORK (Reuters) - U.S. consumer confidence picked up much more strongly than expected in February as Americans shrugged off earlier worries over fiscal policy and tax increases, a private sector report showed on Tuesday.


The Conference Board, an industry group, said its index of consumer attitudes accelerated to 69.6, from a downwardly revised 58.4 in January, handily topping economists' expectations for 61. It was the highest level since November.


January was originally reported as 58.6, the lowest level in more than a year.


Consumers last month had been concerned over the impact of Washington's deal on the "fiscal cliff" at the beginning of the year. While the full brunt of tax increases and spending cuts that were scheduled to go into effect was averted, the payroll tax deduction holiday came to an end and weighed on consumer attitudes in January.


"The shock effect caused by the fiscal cliff uncertainty and payroll tax cuts appears to have abated," Lynn Franco, director of The Conference Board Consumer Research Center, said in a statement.


Still, budget issues remain. Government spending cuts of $85 billion are set to come into effect at the end of the week unless Washington can come to an agreement to postpone what is known as the sequester.


The expectations index climbed to 73.8, from 59.9, while the present situation index gained to 63.3, from 56.2.


Stocks on Wall Street rose to session highs shortly after the data as investors were also taking in a report that showed a jump in new home sales in January, as well as comments from Federal Reserve Chairman Ben Bernanke that strongly defended the central bank's bond-buying stimulus.


"The numbers are all pretty strong. It is a significant rise in confidence and a strong rise in new homes sales - there is not really much to argue in those numbers," said David Sloan, economist at 4Cast Ltd in New York.


Consumers' view on the labor market was mixed. The "jobs hard to get" index edged up to 37 percent from 36.6 percent the month before, while the "jobs plentiful" index also rose to 10.5 percent from 8.5 percent.


Consumers felt better about price increases with expectations for inflation in the coming 12 months falling to 5.5 percent, from 5.7 percent.


(Reporting by Leah Schnurr; Editing by Nick Zieminski)



Read More..

Powers to offer Iran sanctions relief at nuclear talks


ALMATY (Reuters) - Major powers will offer Iran some sanctions relief during talks in Almaty, Kazakhstan, this week if Tehran agrees to curb its nuclear program, a U.S. official said on Monday.


But the Islamic Republic could face more economic pain if it fails to address international concerns about its atomic activities, the official said ahead of the February 26-27 meeting in the central Asian state, speaking on condition of anonymity.


"There will be continued sanctions enforcement ... there are other areas where pressure can be put," the official said, on the eve of the first round of negotiations between Iran and six world powers in eight months.


A spokesman for European Union foreign policy chief Catherine Ashton, who leads the talks with Iran on behalf of the powers, said Tehran should understand that there was an "urgent need to make concrete and tangible progress" in Kazakhstan.


Both Russia and the United States stressed there was not an unlimited amount of time to resolve a dispute that has raised fears of a new war in the Middle East.


"The window for a diplomatic solution simply cannot by definition remain open forever. But it is open today. It is open now," U.S. Secretary of State John Kerry told a news conference in London. "There is still time but there is only time if Iran makes the decision to come to the table and negotiate in good faith."


Russian Deputy Foreign Minister Sergei Ryabkov said there was "no more time to waste", Interfax news agency quoted him as saying in Almaty.


The immediate priority for the powers - the United States, Russia, China, Germany, Britain and France - is to convince Iran to halt its higher-grade enrichment, which is a relatively short technical step away from potential atom bomb material.


Iran, which has taken steps over the last year to expand its uranium enrichment activities in defiance of international demands to scale it back, wants a relaxation of increasingly harsh sanctions hurting its lifeline oil exports.


Western officials say the Almaty meeting is unlikely to produce any major breakthrough, in part because Iran's presidential election in June may make it difficult for it to make significant concessions before then for domestic reasons.


But they say they hope that Iran will take their proposals seriously and engage in negotiations to try to find a diplomatic settlement.


"No one is expecting to walk out of here with a deal but ... confidence building measures are important," one senior Western official said.


The stakes are high: Israel, assumed to be the Middle East's only nuclear-armed arsenal, has strongly hinted at possible military action to prevent its old foe from obtaining such arms. Iran has threatened to retaliate if attacked.


GOLD SANCTIONS RELIEF?


The U.S. official said the powers' updated offer to Iran - a modified version of one rejected by Iran in the unsuccessful talks last year - would take into account its recent nuclear advances but also take "some steps in the sanctions arena".


This would be aimed at addressing some of Iran's concerns, the official said, while making clear it would not meet Tehran's demand of an easing of all punitive steps against it.


"We think ... there will be some additional sanctions relief" in the powers' revised proposal," the official said, without giving details.


Western diplomats have told Reuters the six countries will offer to ease sanctions on trade in gold and precious metals if Iran closes its Fordow underground uranium enrichment plant.


Iran has indicated, however, that this will not be enough.


Tehran denies Western allegations it is seeking to develop the capability to make nuclear bombs, saying its program is entirely peaceful. It wants the powers to recognize what it sees as its right to refine uranium for peaceful purposes.


The U.S. official said the powers hoped that the Almaty meeting would lead to follow-up talks soon.


"We are ready to step up the pace of our meetings and our discussions," the official said, adding the United States would also be prepared to hold bilateral talks with Tehran if it was serious about it.


Ashton's spokesman, Michael Mann, said the updated offer to Iran was "balanced and a fair basis" for constructive talks.


(Additional reporting by Yeganeh Torbati and Dimitry Solovyov; Editing by Jon Hemming)



Read More..

Seth MacFarlane: Why He Didn't Work as Oscar Host









02/25/2013 at 10:30 AM EST



Hosting the Oscars, they say, is a thankless job. So, Seth MacFarlane, thanks for nothing.

This isn't to say he can be blamed for a long evening that seemed to be devoted more to singing than handing out awards.

On the other hand, he doesn't get credit for the show's best moments, either: Adele's powerful performance of "Skyfall," Daniel Day-Lewis's charmingly stiff humor in his acceptance speech for Lincoln – it was so like Abe! – or Michelle Obama's surprising and generous gesture: appearing via satellite to announce the Best Picture winner.

It's also only fair to say that this year's awards weren't as awful as the ones hosted in 2011 by James Franco and Anne Hathaway (her Supporting Actress award for Les Misérables, I suspect, was not only because she made "I Dreamed a Dream" look as painful as a birth scene from Alien, but for being such a good sport about that hosting fiasco). And, given the caliber and popularity of the movies nominated, ratings should be good.

But it's the host who sets the tone, and in that regard MacFarlane was problematic. I say "problematic" in the way that a Secretary of State might describe a report that North Korea had fired a missile in our direction.

The creator-writer of Fox's Family Guy and the hit film Ted, MacFarlane was brought in as a calculated, possibly desperate gamble to liven up the broadcast. He's certainly famous enough, but he's still known principally as a comic sensibility – a voice actor, a joke teller, a writer-director – than as a personality or performer.

And that sensibility is impossible to be indifferent to. MacFarlane likes to be politically and culturally incorrect in a way that registers as annoying, well-aimed tweaks. His jokes can feel like a pencil poked in your back by a student behind you in sixth grade.

I just experienced a most painful flashback to just such an incident.

Maybe the Academy was sold by the fact that, unlike Ricky Gervais and his unnerving, shiny face, MacFarlane looks so harmless, so completely host-appropriate. He arrives as an impeccably groomed package, as smiling and smoothly spoken as Ryan Seacrest. He looks as if he might have managed the Jonas Brothers. He can also sing in the lightly swinging style of classic crooners like Sinatra.

The incongruity doesn't make him funnier.

Why The Funny Man Wasn't So Funny

The night started with one of the strangest and ultimately most pointless openings ever. William Shatner, looking rumpled and cross in his old Star Trek uniform, appeared on a giant screen. He said he had come from the future to warn MacFarlane that his show would be a disaster: "Your jokes are tasteless and inappropriate and everyone ends up hating you."

Then he showed a clip from "further on" in the broadcast: MacFarlane was singing (quite well) about actresses' exposed breasts. Then we saw MacFarlane's "sock puppet" adaptation of the Denzel Washington movie Flight. Shatner said he was appalled that MacFarlane would have the nerve to sock-impersonate a black actor.

In other words, MacFarlane had to explain to us that he would be offensive – because people weren't able to tell? – before he could actually be offensive. This wasn't not so much offensive as irritating and self-aggrandizing.

I actually would have been grateful to be shocked, angered or disgusted rather than patronized.

I mean, it's the Academy Awards, a night that often feels like Hollywood's idea of America's idea of heaven.

This happened to me only once. The "playing off" music – for winners who spoke too long – was the theme from Jaws. This seemed, for a moment, like an inspired, even cute idea, until you realized it came across as sniggering at the statuette-holders as they struggled to cram all they could into their moment of glory. It was like a whoopie cushion, or a wind instrument going "wha-wha-wha-WHAAAA."

(By the time Quentin Tarantino accepted his screenwriter award for Django Unchained with a very long, wildly emphatic speech, Jaws was gone.)

Beyond that, MacFarlane kept throwing out lines, as hosts do, delivering them with a Johnny Carson urbanity even when he was joking, for instance, about how many years it will be before 9-year-old Quvenzhané Wallis can hook up with (or, more precisely, will be too old for) George Clooney.

Then, with all the statuettes given out and the time on the cable box indicating a few minutes past 12 a.m., he and Kristin Chenowith performed a number called "Here's to the Losers."

In a nutshell.

Read More..

FDA approves new targeted breast cancer drug


WASHINGTON (AP) — The Food and Drug Administration has approved a first-of-a-kind breast cancer medication that targets tumor cells while sparing healthy ones.


The drug Kadcyla from Roche combines the established drug Herceptin with a powerful chemotherapy drug and a third chemical linking the medicines together. The chemical keeps the cocktail intact until it binds to a cancer cell, delivering a potent dose of anti-tumor poison.


Cancer researchers say the drug is an important step forward because it delivers more medication while reducing the unpleasant side effects of chemotherapy.


"This antibody goes seeking out the tumor cells, gets internalized and then explodes them from within. So it's very kind and gentle on the patients — there's no hair loss, no nausea, no vomiting," said Dr. Melody Cobleigh of Rush University Medical Center. "It's a revolutionary way of treating cancer."


Cobleigh helped conduct the key studies of the drug at the Chicago facility.


The FDA approved the new treatment for about 20 percent of breast cancer patients with a form of the disease that is typically more aggressive and less responsive to hormone therapy. These patients have tumors that overproduce a protein known as HER-2. Breast cancer is the second most deadly form of cancer in U.S. women, and is expected to kill more than 39,000 Americans this year, according to the National Cancer Institute.


The approval will help Roche's Genentech unit build on the blockbuster success of Herceptin, which has long dominated the breast cancer marketplace. The drug had sales of roughly $6 billion last year.


Genentech said Friday that Kadcyla will cost $9,800 per month, compared to $4,500 per month for regular Herceptin. The company estimates a full course of Kadcyla, about nine months of medicine, will cost $94,000.


FDA scientists said they approved the drug based on company studies showing Kadcyla delayed the progression of breast cancer by several months. Researchers reported last year that patients treated with the drug lived 9.6 months before death or the spread of their disease, compared with a little more than six months for patients treated with two other standard drugs, Tykerb and Xeloda.


Overall, patients taking Kadcyla lived about 2.6 years, compared with 2 years for patients taking the other drugs.


FDA specifically approved the drug for patients with advanced breast cancer who have already been treated with Herceptin and taxane, a widely used chemotherapy drug. Doctors are not required to follow FDA prescribing guidelines, and cancer researchers say the drug could have great potential in patients with earlier forms of breast cancer


Kadcyla will carry a boxed warning, the most severe type, alerting doctors and patients that the drug can cause liver toxicity, heart problems and potentially death. The drug can also cause severe birth defects and should not be used by pregnant women.


Kadcyla was developed by South San Francisco-based Genentech using drug-binding technology licensed from Waltham, Mass.-based ImmunoGen. The company developed the chemical that keeps the drug cocktail together and is scheduled to receive a $10.5 million payment from Genentech on the FDA decision. The company will also receive additional royalties on the drug's sales.


Shares of ImmunoGen Inc. rose 2 cents to $14.32 in afternoon trading. The stock has ttraded in a 52-wek range of $10.85 to $18.10.


Read More..